Pertussis vaccine-acellular, combined with diphtheria and tetanus toxoids (dtap)
Brand: Tripacel
PBAC's latest decision on Pertussis vaccine-acellular, combined with diphtheria and tetanus toxoids (dtap): Recommended (2015). Considered for Prevention of pertussis as an 18-month booster dose in infants.
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2015
Submissions
1
2015 → 2015
Eligible population
Infants aged approximately 18 months requiring a booster dose of pertussis vaccine combined with diphtheria and tetanus toxoids.
Therapy area
Vaccines
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Immunogenicity
Pivotal trial size
1,374 patients
Key trials
Pichichero et al. 1997, Halperin et al. 1996, Halperin et al. 1995, PHASE IIC, Chatterjee et al. 2012, Guerra et al. 2009, Study PERTB9301, Halperin et al. 1994, Pichichero et al. 1996, Nolan et al. 2004, Trofa et al. 2011, Schmitt et al. 1998, Schmitt et al. 1996, NCT00289913, NCT00197236
Comparator
DTPa (Infanrix) as an 18-month booster
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design.